Literature DB >> 19755162

Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.

Thanos D Papakostas1, Rafael Pieretti-Vanmarcke, Fotini Nicolaou, Aristomenis Thanos, George Trichonas, Xanthi Koufomichali, Kosisochukwu Anago, Patricia K Donahoe, Jose Teixeira, David T MacLaughlin, Demetrios Vavvas.   

Abstract

Mullerian Inhibiting Substance (MIS), a member of the TGF-beta family, causes regression of the Mullerian duct in male embryos, after binding to Mullerian Inhibiting Substance Receptor II (MISRII). It has also been extensively demonstrated that it can inhibit proliferation of various cancer cell lines such as ovarian, prostate, and breast cancer in vitro and in vivo. Hence, the availability of a recombinant, epitope tagged, bioactive MIS is important for the selection of patients for treatment and for probing novel molecular targets for MIS in various tissues. To this end, we have expressed a recombinant, internally FLAG-tagged form of hMIS with the tag (DYKDDDDK) immediately after the cleavage site (427-428) of MIS at the C-terminus with a modified dibasic cleavage motif sequence. We show that this construct results in a highly pure, endogenously processed (cleaved) FLAG MIS, that causes complete regression of the Mullerian Duct in an organ culture assay. In addition, purified FLAG MIS was able to bind and affinity purify both transfected and endogenous MIS type II receptor. The availability of this fully functional, epitope tagged form of MIS should facilitate scale-up for preclinical and clinical use and should also be used for the study of MIS binding proteins and for tracking in pharmacokinetic studies. (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19755162      PMCID: PMC3581853          DOI: 10.1016/j.pep.2009.09.004

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  29 in total

Review 1.  Mullerian inhibiting substance: an update.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Adv Exp Med Biol       Date:  2002       Impact factor: 2.622

2.  A graded organ culture assay for the detection of Mullerian inhibiting substance.

Authors:  P K Donahoe; Y Ito; W H Hendren
Journal:  J Surg Res       Date:  1977-08       Impact factor: 2.192

3.  Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.

Authors:  P T Masiakos; D T MacLaughlin; S Maheswaran; J Teixeira; A F Fuller; P C Shah; D J Kehas; M K Kenneally; D M Dombkowski; T U Ha; F I Preffer; P K Donahoe
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

4.  Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.

Authors:  T R Clarke; Y Hoshiya; S E Yi; X Liu; K M Lyons; P K Donahoe
Journal:  Mol Endocrinol       Date:  2001-06

5.  Mapping of the gene for anti-müllerian hormone to the short arm of human chromosome 19.

Authors:  O Cohen-Haguenauer; J Y Picard; M G Mattéi; S Serero; V C Nguyen; M F de Tand; D Guerrier; M C Hors-Cayla; N Josso; J Frézal
Journal:  Cytogenet Cell Genet       Date:  1987

6.  Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.

Authors:  Dorry L Segev; Yasunori Hoshiya; Makiko Hoshiya; Trinh T Tran; Jennifer L Carey; Antonia E Stephen; David T MacLaughlin; Patricia K Donahoe; Shyamala Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

7.  Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Authors:  Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

8.  A mesenchymal perspective of Müllerian duct differentiation and regression in Amhr2-lacZ mice.

Authors:  Nelson A Arango; Akio Kobayashi; Ying Wang; Soazik P Jamin; Hu-Hui Lee; Grant D Orvis; Richard R Behringer
Journal:  Mol Reprod Dev       Date:  2008-07       Impact factor: 2.609

9.  Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells.

Authors:  Yasunori Hoshiya; Vandana Gupta; Hirofumi Kawakubo; Elena Brachtel; Jennifer L Carey; Laura Sasur; Andrew Scott; Patricia K Donahoe; Shyamala Maheswaran
Journal:  J Biol Chem       Date:  2003-10-07       Impact factor: 5.157

10.  Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment.

Authors:  R B Pepinsky; L K Sinclair; E P Chow; R J Mattaliano; T F Manganaro; P K Donahoe; R L Cate
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

View more
  4 in total

Review 1.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

2.  An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.

Authors:  D Pépin; M Hoang; F Nicolaou; K Hendren; L A Benedict; A Al-Moujahed; A Sosulski; A Marmalidou; D Vavvas; P K Donahoe
Journal:  Technology       Date:  2013-09

3.  Production, Isolation, and Structural Analysis of Ligands and Receptors of the TGF-β Superfamily.

Authors:  Tao Huang; Andrew P Hinck
Journal:  Methods Mol Biol       Date:  2016

Review 4.  Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?

Authors:  Swati Agarwal; Faisal A Alzahrani; Asif Ahmed
Journal:  Int J Mol Sci       Date:  2018-10-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.